FDA Submitted Application for Peanut Allergy Patch
The experimental VIASKIN Peanut Patch aims to help children aged 4 to 7 years manage their peanut allergy.
Updated on Sept. 29, 2026 in Allergies
Live Poll
Should the FDA fast-track new immunotherapy treatments for children with food allergies?
DBV Technologies has submitted a Biologics License Application to the FDA for the VIASKIN Peanut Patch. If approved, the patch would provide a new treatment option for children aged 4 through 7 with a peanut allergy.
Why it matters
This application marks a step toward potentially offering a new method for peanut allergy desensitization. The treatment seeks to offer an alternative for families managing severe food allergies in young children.
The application is grounded in results from the Phase 3 VITESSE clinical trial, which followed 654 children over a 12-month double-blind period. Researchers are still awaiting official FDA feedback on the request for Priority Review.
The players
DBV Technologies
A pharmaceutical company headquartered in France that focuses on epicutaneous immunotherapy treatments for food allergies.
FDA
The United States agency responsible for protecting public health by regulating the safety and efficacy of medical products and biologics.
The details
The VIASKIN Peanut Patch uses epicutaneous immunotherapy to deliver 250 µg of allergen protein directly through the skin. This approach is designed to trigger the skin’s immune cells to progressively desensitize children to peanuts without requiring ingestion. The treatment was previously granted Breakthrough Therapy Designation by the FDA for its potential to address an unmet clinical need.
Timeline
September 29, 2026: DBV Technologies submitted the Biologics License Application.
Health Landscape
The VIASKIN Peanut Patch sits within a growing pipeline of immunotherapies designed to shift peanut allergy management from strict avoidance toward active desensitization. This submission follows the FDA's Breakthrough Therapy Designation program, which provides intensive guidance to accelerate the review of new medical therapies.
For parents of children with peanut allergies, this submission indicates that a new treatment modality may be under regulatory review. It is worth discussing with your pediatrician or an allergist whether you should track developments in immunotherapy as part of your child’s long-term care plan.
The takeaway
The development of epicutaneous immunotherapy continues to evolve as a potential method for managing peanut allergies in early childhood. Families should continue to prioritize strict allergen avoidance protocols until further clinical options are cleared by the FDA.
Further reading
For more information on the current standard of care for managing severe sensitivities, visit our Allergies section.
Live Poll
Should the FDA fast-track new immunotherapy treatments for children with food allergies?
